Lonza Expands Viral-Based Therapeutics Business with New cGMP Unit at Houston

Lonza says it will expand its viral-based therapeutics business with the construction of a new cGMP clean room adjacent to its existing Houston operations. The facility will offer large-scale capacity to support late-stage viral vaccine and gene therapy projects. It will use disposable process systems and be able to support production anf fill/finish operations of up to 2,000 liters. Enhanced, EU compliant, fill and finish capabilities are in high demand from Lonza's pharma and biotech customers, the company says. The expansion will also reduce Lonza's clients'...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers